Muramyl peptides in the complex treatment of cervical intraepithelial neoplasia associated with human papillomavirus

Exposure Level ◽

Cervical Lesions ◽

Standard Dosage ◽

Muramyl Peptide ◽

Advanced Therapy ◽

Wide Range ◽

Oncogenic Hpv

Research objective: the use of an immunomodulator III generation with a wide range of action (muramyl peptide drug Liastenum) to increase the effectiveness of treatment of cervical intraepithelial neoplasia grade I associated with human papilloma virus (HPV) and to reduce the recurrence of cervical pathology.Materials and methods. The study included 60 women with histologically confirmed cervical intraepithelial neoplasia associated with highly oncogenic HPV. The mean age of patients was 25.92 ± 0.61 years. The first group included 30 women who received traditional treatment, the second group included 30 women who additional received Liastenum 0.002 g intramuscularly 1 time per day, 5 injections per course, after that patients took 1 tablets Liastenum twice a day for 20 days.Traditional treatment included antibiotic therapy (doxycycline monohydrate), metronidazole, nystatin in standard dosage. Patients with herpes viruses received valaciclovir 500 mg twice/day for 5 days. Evaluation of treatment efficacy was performed at 6 and 12 months with co-testing, fluid cytology, HPV quantification, and colposcopy.Results. There was a significant decrease in the exposure level of highly oncogenic HPV in the second group compared to the first: after 12 months in the first group HPV was not detected in 2 women (6.67%), and in the second group HPV was no detected in 17 women (56.67%) (p < 0.05). Improvement of the colposcopic picture occurred in 70% of patients in the second group, and in 12 (40.0%) of patients colposcopic conclusion on the Swedish scale was less than 3 points after 12 months of observation. Only 8 (26.67%) women received improvement of the colposcopic picture with a score of 3 points on the Swedish scale in the first group, which was significantly different from the second group (p < 0.05).Conclusions. Advanced therapy with muramyl peptide Liastenum in the treatment of cervix for 12 months can increase the effectiveness of HPV elimination, improves the colposcopic picture by reducing the area of cervical lesions and normalized cytological picture in 70% of patients with cervical intraepithelial neoplasia grade I.

Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions

Journal of Clinical Microbiology ◽

10.1128/jcm.00246-15 ◽

2015 ◽

Vol 53 (7) ◽

pp. 2109-2114 ◽

Cited By ~ 11

Author(s):

F. Bottari ◽

M. Sideri ◽

C. Gulmini ◽

S. Igidbashian ◽

A. Tricca ◽

...

Keyword(s):

Human Papillomavirus ◽

Clinical Performance ◽

Absolute Risk ◽

Cervical Lesions ◽

Hybrid Capture ◽

Dna Test ◽

Hpv Dna

Analytical and clinical performance validation is essential before introduction of a new human papillomavirus (HPV) assay into clinical practice. This study compares the new BD Onclarity HPV assay, which detects E6/E7 DNA from 14 high-risk HPV types, to the Hybrid Capture II (HC2) HPV DNA test, to concurrent cytology and histology results, in order to evaluate its performance in detecting high-grade cervical lesions. A population of 567 women, including 325 with ≥ASCUS (where ASCUS stands for atypical cells of undetermined significance) and any HC2 result and 242 with both negative cytology and negative HC2 results, were prospectively enrolled for the study. The overall agreement between Onclarity and HC2 was 94.6% (95% confidence intervals [CI], 92.3% to 96.2%). In this population with a high prevalence of disease, the relative sensitivities (versus adjudicated cervical intraepithelial neoplasia grades 2 and 3 [CIN2+] histology endpoints) of the Onclarity and HC2 tests were 95.2% (95% CI, 90.7% to 97.5%) and 96.9% (95% CI, 92.9% to 98.7%), respectively, and the relative specificities were 50.3% (95% CI, 43.2% to 57.4%) for BD and 40.8% (95% CI, 33.9%, 48.1%) for HC2. These results indicate that the BD Onclarity HPV assay has sensitivity comparable to that of the HC2 assay, with a trend to an increased specificity. Moreover, as Onclarity gives the chance to discriminate between the different genotypes, we calculated the genotype prevalence and the absolute risk of CIN2+: HPV 16 was the most prevalent genotype (19.8%) with an absolute risk of CIN2+ of 77.1%.

Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma

Human Pathology ◽

10.1053/hupa.2000.19443 ◽

2000 ◽

Vol 31 (11) ◽

pp. 1357-1362

Author(s):

Aron Tendler ◽

Howard L. Kaufman ◽

Anna S. Kadish

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Carcinoembryonic Antigen ◽

Squamous Cell ◽

Antigen Expression ◽

Cervical Squamous Cell Carcinoma ◽

Grade 3

The relative risk of noncervical high‐risk human papillomavirus‐related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population‐based study

International Journal of Cancer ◽

10.1002/ijc.32834 ◽

2019 ◽

Vol 147 (3) ◽

pp. 897-900 ◽

Cited By ~ 1

Author(s):

Diede L. Loopik ◽

Renée M. Ebisch ◽

Joanna IntHout ◽

Willem J. Melchers ◽

Leon F. Massuger ◽

...

Keyword(s):

Human Papillomavirus ◽

Relative Risk ◽

High Risk ◽

Population Based ◽

Population Based Study ◽

Grade 3

What is the accuracy of tests used for primary screening for cervical intraepithelial neoplasia grade 3+ (CIN3+)?

Cochrane Clinical Answers ◽

10.1002/cca.3164 ◽

2020 ◽

Author(s):

Jane Burch ◽

Mohammed R Houda

Keyword(s):

Primary Screening ◽

Grade 3

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up ofthree cohorts from randomized trials

BMJ Open ◽

10.1136/bmjopen-2017-015867 ◽

2017 ◽

Vol 7 (8) ◽

pp. e015867 ◽

Cited By ~ 33

Author(s):

Matti Lehtinen ◽

Camilla Lagheden ◽

Tapio Luostarinen ◽

Tiina Eriksson ◽

Dan Apter ◽

...

Keyword(s):

Human Papillomavirus ◽

Cancer Registry ◽

Vaccine Efficacy ◽

Invasive Cervical Cancer ◽

Hpv 16 ◽

Link Type

ObjectiveDue to long lag time between infection/cancer diagnoses human papillomavirus (HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end-points late. Cancer registry follow-up of population-based, randomised trial cohorts of vaccinated and unvaccinated women was undertaken for the estimation of VE against cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+).MethodsWe report interim results with 98 561 person years of Finnish Cancer Registry -based follow-up of individually and/or cluster randomised cohorts of HPV-16/18 vaccinated and unvaccinated adolescent women enrolled in June 2003/2005, and between May 2004 and April 2005, respectively. The cohorts comprised 15 627 18- to 19-year-old unvaccinated women (NCT01393470), and 2 401 and 64 16- to 17-year-old HPV-16/18 vaccinated women participating the PATRICIA (NCT00122681) and HPV-012 (NCT00169494) trials, respectively. The age-aligned passive follow-up started 6 months after the clinical trials’ end.ResultsDuring the follow-up of 4.5 to 10 years post enrolment we identified 75 cases of cervical intraepithelial neoplasia grade 3 (CIN3) and 4 cases of invasive cervical cancer (ICC) in the unvaccinated cohort, and 4 CIN3 cases in the HPV-16/18 vaccinated women. Diagnostic blocks were available for HPV typing from 87% of the cases. CIN3+ lesions were detectable in 54 cases. HPV16 was found in 26 of 50 unvaccinated CIN3+ cases, and in 3 CIN3+ cases in the HPV-16/18 vaccinated women. The latter were all baseline positive for cervical HPV16 DNA. Baseline data was not available for the unvaccinated women. Intention-to-treat VE against any CIN3+ was 66% (95% CI 8, 88).ConclusionsTen years post vaccination the AS04-adjuvanted HPV-16/18 vaccine shows continued efficacy against CIN3+ irrespectively of HPV type. Vaccine efficacy was not observed in baseline HPV16 DNA positive subjects.Trial registration numberNCT01393470.